SLS · SELLAS Life Sciences Group Inc
United States · RS rating 60 · As of 2026-11-03
| Price | 8.87 USD |
|---|---|
| 1-day change | +3.7% |
| RS rating (overall / 1M / 3M / 12M) | 60 / 18 / 26 / 98 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 30 / 26 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +42.6% |
| Market cap (USD) | $833.3M |